UPDATE: Credit Suisse Starts Allergen (AGN) at Neutral, Price Target $76
Tweet
Share
E-mailGet Alerts AGN Hot Sheet
Price: $193.02 --0%
Rating Summary:
8 Buy, 20 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
8 Buy, 20 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Credit Suisse initiated coverage on shares of Allergen (NYSE: AGN) today with a Neutral rating and $76 price target.
The firm comments that AGN offers one of the most attractive stories in the pharmaceutical sector, but is only receiving a Neutral rating as their only have 11% upside potential.The company's performance is driven by the Economy, M&A, and Earnings Revisions. Credit Suisse believes that most of the the positive things going into the future are already known by investors and are priced into the stock.
The firm reports that, "EPS beats in 2011 may be less plausible given potential headwinds on the glaucoma franchise from generic competition [Xalatan] and commercial support for the Botox migraine launch."
For more ratings news on Allergen click here and for the rating history of Allergen click here.
Shares of Allergen closed at $70.13 yesterday.
The firm comments that AGN offers one of the most attractive stories in the pharmaceutical sector, but is only receiving a Neutral rating as their only have 11% upside potential.The company's performance is driven by the Economy, M&A, and Earnings Revisions. Credit Suisse believes that most of the the positive things going into the future are already known by investors and are priced into the stock.
The firm reports that, "EPS beats in 2011 may be less plausible given potential headwinds on the glaucoma franchise from generic competition [Xalatan] and commercial support for the Botox migraine launch."
For more ratings news on Allergen click here and for the rating history of Allergen click here.
Shares of Allergen closed at $70.13 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
- Bernstein SocGen Group Reiterates Outperform Rating on JD.com, Inc (JD), 'very cheaply valued'
- JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
Create E-mail Alert Related Categories
New CoverageRelated Entities
Credit Suisse, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
